Compositions and methods for treating alzheimer's disease and dementia
The present invention relates to a method of treating, preventing, or delaying the onset of Alzheimer's disease and/or dementia in mammals. More particularly, the invention relates to method of administration of compositions containing defined chemical species useful for treating, preventing, or delaying the onset of Alzheimer's disease and/or dementia in mammals. In some embodiments, a composition used in connection with such methods comprises one or more of 1) thyroid hormone and 2) cyclo(His-Pro) and a zinc salt. Such compositions may also be used to treat metabolic syndrome and cerebrovascular diseases.
1. A method of treating or reducing Alzheimer's disease or dementia in a mammal in need thereof, said method comprising: administering at least once daily to the mammal a pharmaceutical composition comprising a zinc salt and cyclo-Hispro; wherein the weight ratio of zinc to cyclo-Hispro is from about 1:100 to about 100:1.
2. The method of claim 1 , wherein the weight ratio of zinc to cyclo-Hispro is from about 1:10 to about 100:1.
3. The method of claim 1 , wherein the weight ratio of zinc to cyclo-Hispro is from about 1:6 to about 5:1.
4. The method of claim 1 , wherein the weight ratio of zinc to cyclo-Hispro is from about 1:15 to about 20:1.
5. The method of claim 1 , wherein the weight ratio of zinc to cyclo-Hispro is from about 1:30 to about 4:1.
6. The method of claim 1 , wherein the weight ratio of zinc to cyclo-Hispro is from about 1:8 to about 4:1.
7. The method of claim 1 , wherein the weight ratio of zinc to cyclo-Hispro is from about 1:40 to about 40:1.
8. The method of claim 1 , further comprising administering a pharmaceutically effective amount of thyroxine to the mammal.
9. A method of treating or reducing Alzheimer's disease or dementia in a mammal in need thereof, said method comprising administering a pharmaceutically effective amount of zinc salt and cyclo-Hispro to the mammal.
10. The method of claim 9 , wherein the zinc salt and cyclo-Hispro are administered in an amount that causes an increased serum level of insulin degrading enzyme in the mammal.
11. The method of claim 9 , wherein the zinc salt and cyclo-Hispro are administered to the mammal in an amount that causes a decrease in a serum level of amyloid beta protein.
12. The method of claim 9 , wherein a zinc cation of the zinc salt is administered to the mammal in an amount from about 0.01 to about 4 mg/kg/day.
13. The method of claim 9 , wherein a zinc cation of the zinc salt is administered to the mammal in an amount from about 0.01 to about 1.5 mg/kg/day.
14. The method of claim 9 , wherein a zinc cation of the zinc salt is administered to the mammal in an amount from about 0.01 to about 0.4 mg/kg/day.
15. The method of claim 9 , wherein a zinc cation of the zinc salt is administered to the mammal in an amount from about 0.1 to about 2 mg/kg/day.
16. The method of claim 9 , wherein a zinc cation of the zinc salt is administered to the mammal in an amount from about 2 to about 4 mg/kg/day.
17. The method of claim 9 , wherein a zinc cation of the zinc salt is administered to the mammal in an amount from about 1 to about 10 mg/kg/day.
18. The method of claim 9 , wherein a zinc cation of the zinc salt is administered to the mammal in an amount from about 3 to about 8 mg/kg/day.
19. The method of claim 9 , wherein a zinc cation of the zinc salt is administered to the mammal in an amount from about 4 to about 7 mg/kg/day.
20. The method of claim 9 , wherein a zinc cation of the zinc salt is administered to the mammal in an amount from about 7 to about 10 mg/kg/day.
21. The method of claim 9 , wherein a zinc cation of the zinc salt is administered to the mammal in an amount from about 0.01 to about 0.1.8 mg/kg/day.
22. The method of claim 9 , wherein a zinc cation of the zinc salt is administered to the mammal in an amount from about 1 to about 1.5 mg/kg/day.
23. The method of claim 9 , wherein cyclo-Hispro is administered to the mammal in an amount from about 0.007 to about 1.4 mg/kg/day.
24. The method of claim 9 , wherein cyclo-Hispro is administered to the mammal in an amount from about 0.01 to about 5 mg/kg/day.
25. The method of claim 9 , wherein cyclo-Hispro is administered to the mammal in an amount from about 0.01 to about 2 mg/kg/day.
26. The method of claim 9 , wherein cyclo-Hispro is administered to the mammal in an amount from about 2 to about 7 mg/kg/day.
27. The method of claim 9 , wherein cyclo-Hispro is administered to the mammal in an amount from about 3 to about 5 mg/kg/day.
28. The method of claim 9 , wherein cyclo-Hispro is administered to the mammal in an amount from about 7 to about 10 mg/kg/day.
29. The method of claim 9 , wherein cyclo-Hispro is administered to the mammal in an amount from about 0.5 to about 2 mg/kg/day.
30. The method of claim 9 , wherein cyclo-Hispro is administered to the mammal in an amount from about 0.2 to about 4 mg/kg/day.
31. The method of claim 9 , wherein cyclo-Hispro is administered to the mammal in an amount from about 0.8 to about 3 mg/kg/day.
32. The method of claim 9 , wherein cyclo-Hispro is administered to the mammal in an amount from about 1 to about 6 mg/kg/day.
33. A method of treating or reducing Alzheimer's disease or dementia in a mammal in need thereof, said method comprising: administering at least once daily to the mammal a pharmaceutical composition comprising L-thyroxine, a zinc cation and anion, and-cyclo-Hispro; wherein L-thyroxine is administered to the mammal in an amount from about 0.1 to about 15 pg/kg/day; and wherein the zinc cation is administered to the mammal in an amount from about 0.01 to about 10 mg/kg/day; and wherein cyclo-Hispro is administered to the mammal in an amount from about 0.001 to about 10 mg/kg/day.
34. A method of treating or reducing Alzheimer's disease or dementia in a mammal in need thereof, said method comprising administering pharmaceutically effective amount of thyroid hormone, a zinc cation with anion, and cyclo-Hispro to a mammal.